Immunoglobulin Light Chain Amyloidosis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: IMM246 MIFTS: 57	Immunoglobulin Light Chain Amyloidosis Categories: Blood diseases, Bone diseases, Cardiovascular diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Metabolic diseases, Nephrological diseases, Neuronal diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Immunoglobulin Light Chain Amyloidosis

MalaCards integrated aliases for Immunoglobulin Light Chain Amyloidosis:

Name: Immunoglobulin Light Chain Amyloidosis ¹¹ ¹⁴

Primary Amyloidosis ¹⁹ ⁵⁸ ⁷¹ ³³

Al Amyloidosis ¹¹ ¹⁹ ⁵⁸ ³³

Primary Systemic Amyloidosis ¹⁹ ⁵⁸ ⁷¹

Light Chain Amyloidosis ¹¹ ¹⁹

Hereditary Amyloid Nephropathy Due to Lysozyme Variant ⁵⁸

Familial Amyloid Nephropathy Due to Lysozyme Variant ⁵⁸

Hereditary Renal Amyloidosis Due to Lysozyme Variant ⁵⁸

Familial Renal Amyloidosis Due to Lysozyme Variant ⁵⁸

Immunoglobulin Light-Chain Amyloidosis ⁴³

Immunoglobulin Deposition Disease ⁷¹

Primary Systemic Al Amyloidosis ¹⁹

Amyloidosis Primary Systemic ¹⁹

Immunoglobulinic Amyloidosis ³³

Systemic Al Amyloidosis ⁵⁸

Light-Chain Amyloidosis ⁵⁸

Primary Al Amyloidosis ¹⁹

Systemic Al Amyloidsis ¹⁹

Lysozyme Amyloidosis ⁵⁸

Amyloidosis Primary ⁵³

Alys Amyloidosis ⁵⁸

Amyloidosis Al ¹⁹

Amyloid Al ³³

Characteristics:

Inheritance:

Alys Amyloidosis: Autosomal dominant ⁵⁸

Prevelance:

Primary Systemic Amyloidosis: 1-5/10000 (Europe) ⁵⁸

Al Amyloidosis: 1-9/100000 (Germany, Worldwide, Worldwide, Europe, Europe, Austria, Austria, Belgium, Bulgaria, Bulgaria, Croatia, Croatia, Cyprus, Czech Republic, Czech Republic, Denmark, Denmark, Estonia, Estonia, Finland, Finland, France, France, Germany, Greece, Greece, Hungary, Hungary, Iceland, Ireland, Italy, Italy, Latvia, Latvia, Liechtenstein, Liechtenstein, Lithuania, Lithuania, Luxembourg, Malta, Malta, Netherlands, Netherlands, Norway, Norway, Poland, Poland, Portugal, Portugal, Romania, Romania, Slovakia, Slovenia, Slovenia, Spain, Spain, Sweden, Sweden, United Kingdom, United Kingdom, Brazil, Canada, Canada, Japan, Japan, Russian Federation, Korea, Republic of, Taiwan, Province of China, Taiwan, Province of China, United States) 1-9/1000000 (Belgium, Cyprus, Iceland, Ireland, Luxembourg, Slovakia, Brazil, Russian Federation, Korea, Republic of, United States) ⁵⁸

Alys Amyloidosis: <1/1000000 (Worldwide) ⁵⁸

Age Of Onset:

Al Amyloidosis: Adult ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Metabolic diseases Genetic diseases
Anatomical: Endocrine diseases Neuronal diseases Nephrological diseases Bone diseases Blood diseases Cardiovascular diseases Gastrointestinal diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Endocrine, nutritional and metabolic diseases

Metabolic disorders

Amyloidosis

Amyloidosis, unspecified

Heredofamilial amyloidosis, unspecified

Neuropathic heredofamilial amyloidosis

Non-neuropathic heredofamilial amyloidosis

Secondary systemic amyloidosis

ICD11: ³³

Endocrine, nutritional or metabolic diseases

Metabolic disorders

Other metabolic disorders

Amyloidosis

AL amyloidosis

Orphanet: ⁵⁸

Rare neurological diseases

Rare renal diseases

Rare systemic and rhumatological diseases

Rare haematological diseases

Sources

Summaries for Immunoglobulin Light Chain Amyloidosis

GARD: ¹⁹ AL amyloidosisis the most common form of amyloidosis, a group of disorders in which an abnormal protein called amyloid builds up in tissues and organs. The signs and symptoms of AL amyloidosis vary among patients because the build up may occur in the tongue, intestines, muscles, joints, nerves, skin, ligaments, heart, liver, spleen, or kidneys. To diagnose AL amyloidosis, healthcare professionals use blood or urine tests to identify signs of amyloid protein and a biopsy to confirm the diagnosis.

MalaCards based summary: Immunoglobulin Light Chain Amyloidosis, also known as primary amyloidosis, is related to amyloid tumor and nephrotic syndrome. An important gene associated with Immunoglobulin Light Chain Amyloidosis is LYZ (Lysozyme), and among its related pathways/superpathways are Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers and Mesenchymal Stem Cells and Lineage-specific Markers. The drugs Thalidomide and Angiogenesis Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include liver, spleen and kidney, and related phenotypes are fatigue and proteinuria

Orphanet ⁵⁸ Al amyloidosis: A clonal B-cell disorder characterized by the aggregation and deposition of insoluble amyloid fibrils derived from misfolding of monoclonal immunoglobulin light chains. It usually presents as systemic AL amyloidosis with involvement of one or more parenchymal organ(s) and, less frequently, as localized amyloidosis with usually nodular deposits restricted to a single organ and/or system.

Alys amyloidosis: A rare, hereditary amyloidosis with primary renal involvement characterized by amyloid deposition in the kidney glomeruli and medulla, gastrointestinal tract, liver, spleen and slow disease progression. Symptoms and signs include nausea, vomiting, dyspepsia, gastritis, gastrointestinal hemorrhage, abdominal pain, hepatic rupture, sicca syndrome, purpura and petechiae, lymphadenopathy and renal dysfunction.

Disease Ontology: ¹¹ An amyloidosis that is characterized by misfolded and aggregated amyloidogenic immunoglobulin light chains produced by marrow clonal plasma cells.

Sources

Related Diseases for Immunoglobulin Light Chain Amyloidosis

Diseases related to Immunoglobulin Light Chain Amyloidosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 623)

#	Related Disease	Score	Top Affiliating Genes
1	amyloid tumor	30.5	TTR B2M
2	nephrotic syndrome	30.4	TTR GSN F9 B2M APOA1 ALB
3	amyloidosis	30.4	TTR SAA1 NPPB MYOM2 LYZ LECT2
4	plasma cell neoplasm	30.4	SDC1 MYOM2 IGHV4-38-2 CD38 B2M
5	monoclonal gammopathy of uncertain significance	30.3	SDC1 MYOM2 IGHV4-38-2 CD38 B2M ALB
6	marginal zone b-cell lymphoma	30.3	SDC1 IGHV4-38-2 CD38
7	waldenstroem's macroglobulinemia	30.3	SDC1 MYOM2 IGHV4-38-2 CD38 B2M
8	carotenemia	30.2	TTR APCS
9	serum amyloid a amyloidosis	30.2	TTR SAA1 B2M APOA1 ALB
10	chromosome 13q14 deletion syndrome	30.2	IGHV4-38-2 CD38
11	monoclonal paraproteinemia	30.2	SDC1 IGHV4-38-2 B2M
12	lymphoplasmacytic lymphoma	30.1	SDC1 MYOM2 IGHV4-38-2 CD38 B2M
13	dialysis-related amyloidosis	30.1	TTR B2M APCS ALB
14	polyneuropathy	30.1	TTR MYOM2 GSN APOA1 ALB
15	smoldering myeloma	30.1	SDC1 MYOM2 IGHV4-38-2 CD38 B2M
16	immunoglobulin heavy chain amyloidosis	30.1	TTR LECT2 GSN APCS
17	demyelinating polyneuropathy	30.0	TTR MYOM2 ALB
18	intermittent claudication	30.0	TNNT2 B2M ALB
19	primary cutaneous amyloidosis	30.0	TTR GSN APCS
20	gamma heavy chain disease	30.0	SDC1 IGHV4-38-2 CD38
21	cardiac arrest	30.0	TNNT2 TNNI3 NPPB
22	restrictive cardiomyopathy	29.9	TTR TNNT2 TNNT1 TNNI3 NPPB
23	hypothyroidism	29.9	TTR NPPB APOA1 ALB
24	pericarditis	29.9	TNNT2 TNNI3 NPPB
25	amyloid neuropathy	29.9	TTR GSN APOA1
26	deficiency anemia	29.9	TTR F9 CD38 B2M ALB
27	congestive heart failure	29.9	TNNT2 TNNI3 NPPB ALB
28	hereditary amyloidosis	29.8	TTR LYZ GSN B2M APOA1
29	diastolic heart failure	29.8	TTR TNNT2 TNNI3 NPPB
30	angina pectoris	29.8	TNNI3 NPPB APOA1
31	amyloidosis, finnish type	29.7	TTR LECT2 GSN APOA1 APCS
32	aortic valve disease 2	29.7	TTR TNNT2 TNNI3 NPPB
33	wild-type amyloidosis	29.7	TTR NPPB GSN B2M APOA1 APCS
34	respiratory failure	29.7	TTR TNNI3 NPPB ALB
35	lymphoma, mucosa-associated lymphoid type	29.6	SDC1 IGLL5 IGHV4-38-2 B2M
36	amyloidosis, hereditary, transthyretin-related	29.6	TTR TNNT2 NPPB GSN B2M APOA1
37	right bundle branch block	29.6	TNNT2 TNNI3 NPPB
38	cardiac tamponade	29.6	TNNI3 NPPB F9 ALB
39	endocarditis	29.5	TTR TNNT2 TNNI3 ALB
40	constrictive pericarditis	29.5	TTR TNNT2 TNNI3 NPPB ALB
41	atrioventricular block	29.5	TNNT2 TNNI3 NPPB
42	extramedullary plasmacytoma	29.5	SDC1 MYOM2 IGHV4-38-2 CD38 B2M ALB
43	type 1 diabetes mellitus	29.5	NPPB B2M APOA1 ALB
44	pulmonary edema	29.5	TNNT2 TNNI3 NPPB
45	leukemia, chronic lymphocytic	29.4	SDC1 IGLL5 IGHV4-38-2 CD38 B2M
46	systolic heart failure	29.3	TNNT2 TNNI3 NPPB ALB
47	mantle cell lymphoma	29.3	SDC1 IGLL5 IGHV4-38-2 CD38 B2M
48	amyloidosis, familial visceral	29.1	TXNRD3 TTR SAA1 LYZ LECT2 GSN
49	pulmonary embolism	28.9	TNNT2 TNNT1 TNNI3 NPPB F9 ALB
50	heart valve disease	28.9	TTR TNNT2 TNNI3 NPPB MYOM2 ALB

Graphical network of the top 20 diseases related to Immunoglobulin Light Chain Amyloidosis:

Sources

Symptoms & Phenotypes for Immunoglobulin Light Chain Amyloidosis

Human phenotypes related to Immunoglobulin Light Chain Amyloidosis:

⁵⁸ ³⁰ (show top 50) (show all 55)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	fatigue ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0012378
2	proteinuria ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000093
3	hypertrophic cardiomyopathy ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001639
4	nephrotic syndrome ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000100
5	weight loss ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001824
6	renal interstitial amyloid deposits ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0032613
7	albuminuria ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0012592
8	monoclonal light chain cardiac amyloidosis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0031326
9	increased circulating antibody level ³⁰	Frequent (33%)		HP:0010702
10	increased circulating nt-probnp concentration ³⁰	Frequent (33%)		HP:0031185
11	increased circulating troponin i concentration ³⁰	Frequent (33%)		HP:0410173
12	increased circulating troponin t concentration ³⁰	Frequent (33%)		HP:0410174
13	hepatomegaly ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002240
14	renal insufficiency ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000083
15	anemia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001903
16	dyspnea ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002094
17	arrhythmia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0011675
18	bruising susceptibility ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000978
19	hypoalbuminemia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0003073
20	constrictive median neuropathy ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0012185
21	obstructive sleep apnea ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002870
22	abdominal distention ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0003270
23	xerostomia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000217
24	abnormal salivary gland morphology ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0010286
25	peripheral edema ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0012398
26	nonproductive cough ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0031246
27	abnormal cardiac ventricle morphology ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001713
28	abnormal cardiac atrium morphology ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0005120
29	postural hypotension with compensatory tachycardia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0005307
30	reduced factor x activity ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0008321
31	autonomic erectile dysfunction ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0008652
32	pulmonary interstitial high-resolution computed tomography abnormality ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0025389
33	jaw claudication ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0030164
34	abnormal p wave ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0031595
35	howell-jolly bodies ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0032550
36	elevated circulating alkaline phosphatase concentration ³⁰	Occasional (7.5%)		HP:0003155
37	dysphagia ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0002015
38	macroglossia ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0000158
39	gastrointestinal hemorrhage ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0002239
40	hoarse voice ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0001609
41	gastroparesis ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0002578
42	abnormality of the liver ⁵⁸		Occasional (29-5%)
43	abnormality of the kidney ⁵⁸		Frequent (79-30%)
44	peripheral neuropathy ⁵⁸		Occasional (29-5%)
45	abnormality of the gastrointestinal tract ⁵⁸		Very rare (<4-1%)
46	increased antibody level in blood ⁵⁸		Frequent (79-30%)
47	abnormal heart morphology ⁵⁸		Frequent (79-30%)
48	reduced ejection fraction ⁵⁸		Excluded (0%)
49	interstitial pulmonary abnormality ⁵⁸		Frequent (79-30%)
50	elevated alkaline phosphatase ⁵⁸		Occasional (29-5%)

Sources

Drugs & Therapeutics for Immunoglobulin Light Chain Amyloidosis

Drugs for Immunoglobulin Light Chain Amyloidosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Thalidomide

Approved, Investigational, Withdrawn

Phase 4

50-35-1

5426

Angiogenesis Inhibitors

Phase 4

Anti-Bacterial Agents

Phase 4

Anti-Infective Agents

Phase 4

Mechlorethamine

Approved, Investigational

Phase 3

51-75-2

4033

Daratumumab

Approved

Phase 3

945721-28-8

Doxycycline

Approved, Investigational, Vet_approved

Phase 2, Phase 3

564-25-0

54671203

Melphalan

Approved

Phase 3

148-82-3

4053 460612

Lenograstim

Approved, Investigational

Phase 3

135968-09-1

D-Phenylalanine

Approved, Experimental, Investigational, Nutraceutical

Phase 3

63-91-2, 673-06-3

6140 71567

Pharmaceutical Solutions

Phase 3

Antiprotozoal Agents

Phase 2, Phase 3

Antiparasitic Agents

Phase 2, Phase 3

Antimalarials

Phase 2, Phase 3

Adjuvants, Immunologic

Phase 3

Immunoglobulin G

Phase 3

Iodine

Approved, Investigational

Phase 2

7553-56-2

807

Cianidanol

Approved, Withdrawn

Phase 2

154-23-4

9064

Silicon

Approved, Investigational

Phase 2

7440-21-3

4082203

Sorbitol

Approved, Investigational

Phase 2

69-65-8, 50-70-4

453 6251 5780

Coenzyme M

Approved, Investigational

Phase 2

3375-50-6

598 23662354

Busulfan

Approved, Investigational

Phase 2

55-98-1

2478

Etoposide

Approved

Phase 2

33419-42-0

36462

Cisplatin

Approved

Phase 2

15663-27-1

2767 5702198 441203

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Fludarabine

Approved

Phase 1, Phase 2

75607-67-9, 21679-14-1

30751 657237

Mycophenolic acid

Approved, Investigational

Phase 1, Phase 2

24280-93-1

446541

Miconazole

Approved, Investigational, Vet_approved

Phase 1, Phase 2

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 1, Phase 2

23593-75-1

2812

Sargramostim

Approved, Investigational

Phase 2

123774-72-1

Lenalidomide

Approved

Phase 1, Phase 2

191732-72-6

216326

Pomalidomide

Approved

Phase 1, Phase 2

19171-19-8

134780

Venetoclax

Approved, Investigational

Phase 1, Phase 2

1257044-40-8

49846579

Edetate calcium disodium anhydrous

Approved, Vet_approved

Phase 1, Phase 2

62-33-9, 60-00-4

6049

Pentetic acid

Approved

Phase 1, Phase 2

67-43-6

Heparin, bovine

Approved, Investigational, Withdrawn

Phase 1, Phase 2

9005-49-6

22833565 9812414 772

Ixazomib

Approved, Investigational

Phase 1, Phase 2

1072833-77-2

25183872

Gliclazide

Approved

Phase 2

21187-98-4

3475

Cyclophosphamide

Approved, Investigational

Phase 1, Phase 2

50-18-0, 6055-19-2

2907

Elotuzumab

Approved

Phase 2

915296-00-3

Sodium citrate

Approved, Investigational

Phase 1, Phase 2

68-04-2

23431961

Siltuximab

Approved, Investigational

Phase 2

541502-14-1

Etanercept

Approved, Investigational

Phase 2

185243-69-0

Amiodarone

Approved, Investigational

Phase 2

1951-25-3

2157

Glycine

Approved, Nutraceutical, Vet_approved

Phase 1, Phase 2

56-40-6

750

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 1, Phase 2

77-92-9

311

Cadexomer iodine

Experimental

Phase 2

94820-09-4

Epicatechin

Investigational

Phase 2

490-46-0

58571364 72276

Molgramostim

Investigational

Phase 2

99283-10-0

Epigallocatechin gallate

Investigational

Phase 2

989-51-5

65064

Interventional clinical trials:

(show top 50) (show all 140)

#	Name	Status	NCT ID	Phase	Drugs
1	A Comparative Study of Bortezomib-Thalidomide-Dexamethason and Bortezomib-Cyclophosphamide-Dexamethason in the Treatment of Monoclonal Immunoglobulin Light Chain Amyloidosis: A Prospective Randomized Controlled Trial（BTD-CHINA-TRIAL）	Recruiting	NCT04612582	Phase 4	Thalidomide;Cyclophosphamide
2	Frontline Lenalidomide for AL Amyloidosis Involving Myocardium: Investigation of Organ Reversing Capacity of Lenalidomide	Unknown status	NCT04298372	Phase 3	Lenalidomide 25mg
3	Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone in Patients With AL (Primary)Amyloidosis. A Prospective Randomized Trial .	Completed	NCT00344526	Phase 3	Melphalan;Dexamethasone
4	A Randomized Open-label Multicenter Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients With Systemic Light-chain (AL) Amyloidosis	Completed	NCT01277016	Phase 3	BMDex
5	Induction Therapy With Bortezomib and Dexamethasone Followed by Autologous Stem Cell Transplantation Versus Autologous Stem Cell Transplantation Alone in the Treatment of AL Amyloidosis	Completed	NCT01998503	Phase 3	Bortezomib;dexamethasone;Melphalan
6	A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis	Completed	NCT01659658	Phase 3	IXAZOMIB;Dexamethasone;Melphalan;Cyclophosphamide;Thalidomide;Lenalidomide
7	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients With Systemic Light-Chain (AL) Amyloidosis Ineligible for Autologous Stem-Cell Transplantation	Completed	NCT01078454	Phase 3	melphalan;dexamethasone;bortezomib
8	Phase III Trial of Stem Cell Transplantation Compared to Parenteral Melphalan and Oral Dexamethasone in the Treatment of Primary Systemic Amyloidosis (AL)	Completed	NCT00477971	Phase 3	dexamethasone;melphalan
9	A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Naïve Patients With Mayo Stage IIIb AL Amyloidosis	Recruiting	NCT04504825	Phase 3	CAEL-101;cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen
10	A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Naïve Patients With Mayo Stage IIIa AL Amyloidosis	Recruiting	NCT04512235	Phase 3	CAEL-101;cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen
11	A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects With Light Chain (AL) Amyloidosis	Recruiting	NCT04973137	Phase 3	Birtamimab;Standard of Care Chemotherapy
12	A Randomized Phase II/III Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy	Active, not recruiting	NCT03474458	Phase 2, Phase 3	Doxycycline;Standard of care therapy
13	A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis	Active, not recruiting	NCT03201965	Phase 3	Cyclophosphamide;Bortezomib;Dexamethasone, 40 mg;Daratumumab
14	An Open-label, Multi-center, Non-randomized Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of [18F]Florbetaben Positron Emission Tomography (PET) Imaging to Diagnose Cardiac AL Amyloidosis	Not yet recruiting	NCT05184088	Phase 3	[18F]florbetaben
15	Phase III Trial of High-dose Melphalan and Stem Cell Transplantation Versus High-dose Melphalan and Bortezomib and Stem Cell Transplantation in Patients With AL Amyloidosis	Terminated	NCT02489500	Phase 3	Bortezomib;Melphalan;Neupogen
16	A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis	Terminated	NCT02312206	Phase 3	NEOD001
17	Randomized Phase II Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden in High Risk Patients With Multiple Myeloma or Amyloidosis	Completed	NCT00651937	Phase 2	Melphalan;Granulocyte-colony stimulating factor (G-CSF)
18	A Phase 1/2, Open Label, Dose Escalation Study of Intravenous Administration of Single Agent NEOD001 in Subjects With Light Chain (AL) Amyloidosis	Completed	NCT01707264	Phase 1, Phase 2	NEOD001
19	A Prospective Single Center Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With AL Amyloidosis	Completed	NCT00883623	Phase 2	Lenalidomide
20	An Open-label, Phase II Study of Pomalidomide and Dexamethasone (PDex) for Previously Treated Patients With AL Amyloidosis.	Completed	NCT01510613	Phase 2	Pomalidomide and Dexamethasone
21	Phase II Trial of 4'-IODO-4'-Deoxydoxorubicin in Primary Amyloidosis (AL)	Completed	NCT00003853	Phase 2	4'-iodo-4'-deoxydoxorubicin
22	High Dose Chemotherapy and Autologous Stem Cell Rescue for Primary Amyloidosis	Completed	NCT00186407	Phase 2
23	Autologous Peripheral Blood Stem Cell Transplantation With High Dose Melphalan For Treatment Of Primary Amyloidosis (AL)	Completed	NCT00002810	Phase 2	melphalan
24	Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis (DUAL) Trial: A Phase II Open Label Study of Oral Doxycycline Administered as an Adjunct to Plasma Cell Directed Therapy in Light Chain (AL) Amyloidosis	Completed	NCT02207556	Phase 2	Doxycycline
25	A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction	Completed	NCT02632786	Phase 2	NEOD001;Placebo
26	A Randomised Trial for the Treatment of Cardiac AMyloid Light-chain Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)	Completed	NCT02015312	Phase 2	Epigallocatechin-3-gallate (EGCG);Placebo
27	Phase 1/2 Study Of Ixazomib In Combination With Cyclophosphamide And Dexamethasone In Patients With Newly Diagnosed Immunoglobulin Light Chain AL Amyloidosis	Completed	NCT03236792	Phase 1, Phase 2	Ixazomib;Cyclophosphamide;Dexamethasone
28	A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis	Completed	NCT01570387	Phase 1, Phase 2	Pomalidomide;Dexamethasone
29	A Phase I-II Trial of Daratumumab for the Treatment of Patients With AL Amyloidosis	Completed	NCT02841033	Phase 1, Phase 2	daratumumab
30	Phase II Study of the Combination of Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis	Completed	NCT01222260	Phase 2	Bendamustine;Dexamethasone
31	Phase II Trial of High-dose Melphalan and Bortezomib and Stem Cell Transplantation in Patients With AL Amyloidosis	Completed	NCT00790647	Phase 2	bortezomib;melphalan
32	Therapeutic Potential of Human Immune Globulin Intravenous (IGIV) in Patients With Cardiac-Associated Light Chain (AL) Amyloidosis	Completed	NCT00547365	Phase 1, Phase 2
33	Risk-Adapted Intravenous Melphalan With Stem Cell Transplant and Adjuvant Bortezomib and Dexamethasone for Recently Diagnosed Untreated Patients With Systemic Light-Chain (AL) Amyloidosis	Completed	NCT00458822	Phase 2	bortezomib;dexamethasone
34	A Phase II Trial of MRD (Melphalan, Lenalidomide and Dexamethasone) for Patients With AL Amyloidosis	Completed	NCT00679367	Phase 2	dexamethasone;lenalidomide;melphalan
35	A Phase II Trial of the Immunomodulatory Drug CC-5013 for Patients With AL Amyloidosis	Completed	NCT00091260	Phase 2	dexamethasone;lenalidomide
36	A Phase II Trial of Tandem Transplantation in AL Amyloidosis	Completed	NCT00075621	Phase 2	filgrastim;melphalan
37	Phase II Study of Dexamethasone/Alpha-Interferon in AL Amyloidosis	Completed	NCT00002849	Phase 2	dexamethasone
38	S0115, A Phase II Trial Evaluating Modified High Dose Melphalan (100 mg/m) And Autologous Peripheral Blood Stem Cell Supported Transplant (SCT) For High Risk Patients With Multiple Myeloma And/Or Light Chain Amyloidosis (AL Amyloidosis) (A BMT Study)	Completed	NCT00064337	Phase 2	cyclophosphamide;dexamethasone;melphalan;thalidomide
39	A Multicentre Open Label Phase II Study of Daratumumab in AL Amyloidosis Patients Not in VGPR or Better	Completed	NCT02816476	Phase 2	Daratumumab
40	A Single Arm Open Labeled Multicentre Phase 1b Dose Escalation Study of Carfilzomib Taken in Combination With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis	Completed	NCT02545907	Phase 1, Phase 2	Carfilzomib;Thalidomide;Dexamethasone
41	Phase II Trial of Induction Therapy With Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation in Patients With AL Amyloidosis	Completed	NCT01083316	Phase 2	Bortezomib;Dexamethasone;Melphalan
42	An Open-Label Phase 1/2 Study of VELCADE for Injection in Subjects With Light-Chain (AL)-Amyloidosis	Completed	NCT00298766	Phase 1, Phase 2	VELCADE
43	A Multicenter Phase I/II Dose Escalation Study of Lenalidomide in Combination With Melphalan and Dexamethasone in Subjects With Newly-diagnosed Light-chain (AL)-Amyloidosis	Completed	NCT00621400	Phase 1, Phase 2	Lenalidomide;Melphalan;Dexamethasone
44	An Open-label, Phase II Study of Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis	Completed	NCT00607581	Phase 2	cyclophosphamide;lenalidomide;dexamethasone
45	Risk-adapted Therapy for AL Amyloidosis	Completed	NCT01527032	Phase 2	melphalan, thalidomide and dexamethasone
46	Single Autologous Transplant Followed by Consolidation and Maintenance for Participants ≥ 65 Years of Age Diagnosed With Multiple Myeloma or a Related Plasma Cell Malignancy	Completed	NCT01849783	Phase 2	dexamethasone;cisplatin;doxorubicin;cyclophosphamide;etoposide;bortezomib;thalidomide;melphalan
47	Phase II Study of Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Light Chain Amyloidosis	Completed	NCT01072773	Phase 2	bortezomib;cyclophosphamide;dexamethasone
48	Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil	Completed	NCT00006251	Phase 1, Phase 2	fludarabine phosphate;cyclosporine;mycophenolate mofetil
49	A Multicentric, Phase II Trial of Lenalidomide, Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed, Not Candidates for Hematopoietic Stem Cell Transplantation	Completed	NCT01194791	Phase 2	Lenalidomide;Cyclophosphamide;Dexamethasone
50	Risk Adapted Intravenous Melphalan and Adjuvant Thalidomide and Dexamethasone for Untreated Patients With Primary Systemic Amyloidosis	Completed	NCT00089167	Phase 2	dexamethasone;melphalan;thalidomide

Search NIH Clinical Center for Immunoglobulin Light Chain Amyloidosis

Cochrane evidence based reviews: immunoglobulin light-chain amyloidosis

Sources

Genetic Tests for Immunoglobulin Light Chain Amyloidosis

Sources

Anatomical Context for Immunoglobulin Light Chain Amyloidosis

Organs/tissues related to Immunoglobulin Light Chain Amyloidosis:

MalaCards : Liver, Spleen, Kidney, Tongue, Heart, Bone, Salivary Gland

Sources

Publications for Immunoglobulin Light Chain Amyloidosis

Articles related to Immunoglobulin Light Chain Amyloidosis:

(show top 50) (show all 5041)

#	Title	Authors	PMID	Year
1	The molecular biology and clinical features of amyloid neuropathy. ⁵³ ⁶²	Benson MD...Kincaid JC	17554795	2007
2	Current treatment in cardiac amyloidosis. ⁵³ ⁶²	Kholova I...Kautzner J	17078911	2006
3	[Case of primary amyloidosis complicated with intramuscular hemorrhage and Factor IX and X deficiencies]. ⁵³ ⁶²	Suhara Y...Saito S	2061641	1991
4	Daratumumab in AL amyloidosis. ⁶²	Wechalekar AD...Sanchorawala V	35507692	2022
5	The clinical features and outcomes of systemic light chain amyloidosis with hepatic involvement. ⁶²	Zhao L...Huang X	35481407	2022
6	Diagnostic amyloid light chain amyloidosis hospitalizations associated with high acuity and cost: analysis of the Premier Healthcare Database. ⁶²	D'Souza A...Quock TP	36268951	2022
7	Pilot Trial of Homebound Hematopoietic Cell Transplantation. ⁶²	Landau HJ...Giralt SA	36182105	2022
8	Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment. ⁶²	Martinez-Naharro A...Fontana M	36239754	2022
9	Myocardial Uptake of 68Ga-Pentixafor in a Patient With Systemic Amyloidosis. ⁶²	Pan Q...Li J	36342801	2022
10	Real-Life Evaluation of an Algorithm for the Diagnosis of Cardiac Amyloidosis. ⁶²	Bezard M...Damy T	36464537	2022
11	AL-Type Amyloidosis Involving Stomach and Lungs in 99m Tc-DPD Bone Scan. ⁶²	Lee Y...O JH	35835133	2022
12	Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis. ⁶²	Kfir-Erenfeld S...Gatt ME	36107221	2022
13	Plasma cell neoplasms and related entities-evolution in diagnosis and classification. ⁶²	Fend F...Cook JR	36414803	2022
14	Correction: First report of CART treatment in AL Amyloidosis and relapsed/refractory multiple myeloma. ⁶²		36328380	2022
15	A multidisciplinary case report of multiple myeloma with renal and cardiac involvement: a look beyond amyloidosis. ⁶²	Innocenti S...Stefano P	36397026	2022
16	Isolated prostate amyloidosis; a case report. ⁶²	Sibley RR...Van Gorder MA	36164377	2022
17	Modified High-Dose versus High-Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis. ⁶²	Hassan H...Edwards CV	35970300	2022
18	Orbital amyloidosis and radiotherapy: A case report and review of literature. ⁶²	Bennassi A...Khanfir K	35918273	2022
19	Primary amyloidosis of conjunctiva. ⁶²	Jha K...Bhattacharyya M	36467837	2022
20	Diving in the big blue: Atypical Mott cells in rapidly fatal primary amyloidosis. ⁶²	Rwayane K...Eveillard M	36467785	2022
21	Suspecting and diagnosing transthyretin amyloid cardiomyopathy (ATTR-CM) in India: An Indian expert consensus. ⁶²	Chander Mohan J...Radhakrishnan V	36410415	2022
22	[Cardiac amyloidosis - important differential diagnosis in heart failure]. ⁶²	Morbach C...Stork S	36384153	2022
23	Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Distribution in a Mexican Population. ⁶²	de la Cruz Jasso MA...Uribe-Uribe NO	36370056	2022
24	Low QRS Voltages in Cardiac Amyloidosis: Clinical Correlates and Prognostic Value. ⁶²	Cipriani A...Rapezzi C	36444225	2022
25	Outcomes of heart transplantation in cardiac amyloidosis: an updated systematic review. ⁶²	Lakhdar S...Munira MS	35595919	2022
26	Clinical features and outcomes of renal amyloidosis in Hong Kong. ⁶²	Lin RCC...Fung SKS	36054582	2022
27	Macroglossia in rapidly progressive inclusion body myositis. ⁶²	Yamasaki Y...Ando Y	36349419	2022
28	Alcohol septal ablation for left ventricular outflow tract obstruction in cardiac amyloidosis: New indication for an established therapy. ⁶²	Fanta LE...Reilly NM	36153647	2022
29	With M-protein positive, could transthyretin amyrodosis be easily excluded? Not necessarily! Wild-type transthyretin amyrodosis with Waldenström's macroglobulinaemia: a case report. ⁶²	Kinoshita H...Oka T	36339457	2022
30	Feasibility of 68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT in Light-Chain Cardiac Amyloidosis. ⁶²	Wang X...Huo L	36357138	2022
31	Clinical Outcomes and Effectiveness of Heart Transplantation in Patients With Systemic Light-chain Cardiac Amyloidosis. ⁶²	Jeong H...Kim JJ	35706094	2022
32	Advances in the treatment of light chain amyloidosis. ⁶²	Palladini G...Milani P	35943427	2022
33	Concurrent light chain amyloidosis and proximal tubulopathy: Insights into different aggregation behavior-A case report. ⁶²	Feurstein S...Hegenbart U	36467828	2022
34	Systemic light chain amyloidosis myopathy responsive to daratumumab monotherapy. ⁶²	Chitimus DM...Lefeuvre C	36403110	2022
35	Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial. ⁶²	Minnema MC...Jaccard A	36444227	2022
36	[Interest of daratumumab in refractory AL amyloidosis in a 96-year-old patient]. ⁶²	Vial G...Ribeiro E	35934598	2022
37	Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival. ⁶²	Basset M...Palladini G	35772003	2022
38	Understanding real-world treatment patterns and clinical outcomes in AL amyloidosis patients diagnosed in Canada: A population-based cohort study. ⁶²	Jimenez-Zepeda VH...Boyne DJ	36467790	2022
39	AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: JACC: CardioOncology State-of-the-Art Review. ⁶²	Wechalekar AD...Liedtke M	36444232	2022
40	Role of Daratumumab in Cardiac AL Amyloidosis. ⁶²	Gertz MA	36444231	2022
41	A rare case of isolated laryngotracheal amyloidosis with airway narrowing and vocal fold involvement. ⁶²	Ahmed M...Hammill P	36065250	2022
42	Treatment of Localized Amyloid Light Chain Amyloidosis With External Beam Radiation Therapy. ⁶²	Hall J...Chera B	36088238	2022
43	Validation of an administrative coding algorithm for the identification of individuals with amyloid light chain amyloidosis using administrative data. ⁶²	Jimenez-Zepeda VH...Boyne DJ	36409003	2022
44	Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis. ⁶²	Muchtar E...Gertz MA	36215675	2022
45	Monoclonal Gammopathies of Clinical Significance: A Critical Appraisal. ⁶²	Rios-Tamayo R...Duarte RF	36358666	2022
46	Treatment of amyloid light chain cardiac amyloidosis: systematic review and future directions. ⁶²	Alsomali D...Hashmi SK	36206073	2022
47	Truncal sensory polyneuropathy in light-chain amyloidosis. ⁶²	Clarke AJ...Halmagyi GM	36288916	2022
48	Unusual purpura as a first sign of amyloid light chain amyloidosis. ⁶²	Li Y...Jiang Y	36174634	2022
49	Violaceous truncal plaques consistent with amyloid light-chain amyloidosis. ⁶²	Beer J...Seykora JT	34263931	2022
50	A prospective, randomized trial of patient-reported outcome measures to drive management decisions in hematology and oncology. ⁶²	Warsame R...Dueck AC	35928285	2022

Sources

Genes for Immunoglobulin Light Chain Amyloidosis

Genes related to Immunoglobulin Light Chain Amyloidosis (1 elite genes):

(show all 21)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	LYZ	Lysozyme	Protein Coding	354.32	Causative germline mutation ⁵⁸ DISEASES inferred ¹⁴	11849445 12675840
2	TTR	Transthyretin	Protein Coding	25.24	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	14604984 17078911 17554795
3	TXNRD3	Thioredoxin Reductase 3	Protein Coding	8.66	DISEASES inferred ¹⁴ ¹⁴
4	F9	Coagulation Factor IX	Protein Coding	7.83	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	2061641
5	MYOM2	Myomesin 2	Protein Coding	7.78	DISEASES inferred ¹⁴
6	APCS	Amyloid P Component, Serum	Protein Coding	7.68	DISEASES inferred ¹⁴
7	CD38	CD38 Molecule	Protein Coding	7.24	DISEASES inferred ¹⁴
8	B2M	Beta-2-Microglobulin	Protein Coding	7.19	DISEASES inferred ¹⁴
9	NPPB	Natriuretic Peptide B	Protein Coding	7.12	DISEASES inferred ¹⁴
10	LECT2	Leukocyte Cell Derived Chemotaxin 2	Protein Coding	6.88	DISEASES inferred ¹⁴
11	SDC1	Syndecan 1	Protein Coding	6.76	DISEASES inferred ¹⁴
12	ALB	Albumin	Protein Coding	6.54	DISEASES inferred ¹⁴
13	TNNT2	Troponin T2, Cardiac Type	Protein Coding	6.5	DISEASES inferred ¹⁴
14	GSN	Gelsolin	Protein Coding	6.45	DISEASES inferred ¹⁴
15	SAA1	Serum Amyloid A1	Protein Coding	6.38	DISEASES inferred ¹⁴
16	APOA1	Apolipoprotein A1	Protein Coding	6.29	DISEASES inferred ¹⁴
17	IGLL5	Immunoglobulin Lambda Like Polypeptide 5	Protein Coding	6.08	DISEASES inferred ¹⁴
18	IGHV4-38-2	Immunoglobulin Heavy Variable 4-38-2	Protein Coding	6.02	DISEASES inferred ¹⁴
19	TNNT1	Troponin T1, Slow Skeletal Type	Protein Coding	6	DISEASES inferred ¹⁴
20	TNNI3	Troponin I3, Cardiac Type	Protein Coding	5.96	DISEASES inferred ¹⁴
21	APOA2	Apolipoprotein A2	Protein Coding	5.88	DISEASES inferred ¹⁴

Sources

Variations for Immunoglobulin Light Chain Amyloidosis

Sources

Expression for Immunoglobulin Light Chain Amyloidosis

Search GEO for disease gene expression data for Immunoglobulin Light Chain Amyloidosis.

Sources

Pathways for Immunoglobulin Light Chain Amyloidosis

Pathways related to Immunoglobulin Light Chain Amyloidosis according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers ⁶⁵	11.67	TNNT2 TNNI3 ALB
2	Mesenchymal Stem Cells and Lineage-specific Markers ⁶⁵	11.48	TNNT2 TNNI3 SDC1
3	Binding and Uptake of Ligands by Scavenger Receptors ⁶⁶ Show member pathways Scavenging by Class A Receptors ⁶⁶ Scavenging by Class B Receptors ⁶⁶ Scavenging by Class F Receptors ⁶⁶ Scavenging by Class H Receptors ⁶⁶ Scavenging of heme from plasma ⁶⁶	11.39	SAA1 APOA1 ALB
4	Striated muscle contraction pathway ⁷⁴ Show member pathways Striated Muscle Contraction ⁶⁶	11.2	TNNT2 TNNT1 TNNI3
5	Ca, cAMP and Lipid Signaling ³	11.12	TNNI3 GSN CD38 APOA1 ALB
6	FOXA2 and FOXA3 transcription factor networks ⁶¹ Show member pathways FOXA transcription factor networks ⁶¹	10.77	TTR APOA1 ALB

Sources

GO Terms for Immunoglobulin Light Chain Amyloidosis

Cellular components related to Immunoglobulin Light Chain Amyloidosis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	10.4	TTR NPPB LYZ LECT2 GSN F9
2	extracellular exosome	GO:0070062	10.23	ALB APCS APOA1 B2M CD38 F9
3	extracellular region	GO:0005576	10.02	ALB APCS APOA1 B2M F9 GSN
4	blood microparticle	GO:0072562	9.92	ALB APCS APOA1 GSN
5	cardiac myofibril	GO:0097512	9.67	TNNT2 TNNI3
6	cardiac Troponin complex	GO:1990584	9.56	TNNT2 TNNI3
7	troponin complex	GO:0005861	9.1	TNNT2 TNNT1 TNNI3

Biological processes related to Immunoglobulin Light Chain Amyloidosis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	retina homeostasis	GO:0001895	9.8	LYZ B2M ALB
2	sarcomere organization	GO:0045214	9.73	TNNT2 TNNT1 MYOM2
3	muscle contraction	GO:0006936	9.7	TNNT2 TNNT1 TNNI3 MYOM2
4	regulation of system process	GO:0044057	8.96	TNNT2 TNNT1
5	regulation of muscle contraction	GO:0006937	8.8	TNNT2 TNNT1 TNNI3

Molecular functions related to Immunoglobulin Light Chain Amyloidosis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	identical protein binding	GO:0042802	10.13	TTR TNNT2 SDC1 LYZ LECT2 CD38
2	troponin T binding	GO:0031014	9.26	TNNT1 TNNI3
3	troponin C binding	GO:0030172	8.92	TNNT2 TNNI3